Menu
Your Cart

Amiksin IC of the tab. of p/o 0.125g No. 3

Amiksin IC of the tab. of p/o 0.125g No. 3
Amiksin IC of the tab. of p/o 0.125g No. 3
Amiksin IC of the tab. of p/o 0.125g No. 3
Amiksin IC of the tab. of p/o 0.125g No. 3
Amiksin IC of the tab. of p/o 0.125g No. 3
$26.83
Tax $26.83
  • Stock: In Stock
  • Model: 176126

0% Customers recommend this product

  • 5 Awesome
    0%
  • 4 Great
    0%
  • 3 Average
    0%
  • 2 Bad
    0%
  • 1 Poor
    0%

Reviews Over Amiksin IC of the tab. of p/o 0.125g No. 3

  • (0)

Total Reviews (0)
click here write review to add review for this product.



Description

Pharmacological properties

Pharmacodynamics. amiksin ic (tiloron) — immunomodulatory and antiviral means. stimulates education in an organism α-, β-, γ-interferon. the main producers of interferon in response to introduction of an amiksin of ic are intestines epithelium cells, hepatocytes, T lymphocytes, neutrophils and granulocytes. after intake the maximum products of interferon are defined in the sequence intestines — a liver — blood in 4–24 h stimulates stem cells of marrow, depending on a dose strengthens antibodyformation, reduces immunosuppression degree, restores a ratio t suppressors / t-helpery. it is effective concerning a wide range of viral infections, including against influenza viruses, other SARS, hepatitis a, v, s, herpes viruses. the mechanism of antiviral action is connected with inhibition of broadcast of virus-specific proteins in the infected cages owing to what the reproduction of viruses is oppressed.

to

When carrying out researches on animals (chicken and duck embryos) proved high antiviral activity of medicine concerning the causative agent of highly pathogenic avian influenza (VPPG) of a strain H5N1 and also (when carrying out experiments on hens) the considerable immunostimulating and adjuvant activity concerning VPPG activator antigens.

Pharmacokinetics. After intake tiloron it is quickly soaked up in a GIT. The bioavailability is 60%. About 80% of medicine contact proteins of blood plasma. Drug is not exposed to biotransformation and does not collect in an organism. It is removed practically in not changed view with a stake and urine in the ratio 7:1. The t ½ makes 48 h

Indication

Adult: treatment of a viral hepatitis a, v, s, a herpes infection, a Cytomegaloviral infection, as a part of complex therapy infectious and allergic and viral encephalomyelitis (multiple sclerosis, a leukoencephalitis, uveoentsefalit also an encephalomeningitis), urogenital and respiratory clamidiosis; treatment and prevention of flu and other SARS. for decrease in degree of an immunosuppression as a part of complex therapy of the diseases which are followed by the secondary induced immunodeficience (caused by influence of x-ray emission, tsitostatik, surgical interventions, etc.) and demanding immunocorrection.

Children are aged more senior than 7 years: for treatment of flu and other SARS.

Use

Drug is taken inside after a meal.

Adult

Prevention of a viral hepatitis And — 125 mg/week for 6 weeks

Treatment of a viral hepatitis And — in the first day on 125 mg 2 times a day, after that — on 125 mg with an interval of 48 h. A course dose — 1.25 g

Treatment of an acute hepatitis In — in the first 2 days on 125 mg, after that — on 125 mg with an interval of 48 h. A course dose — 2 g. At a long course of hepatitis B the course dose can be raised to 2.5 g

In chronic hepatitis B — in the first 2 days accept 250 mg, after that — on 125 mg with an interval of 48 h. A course dose in an initiation of treatment — 2.5 g. Further the medicament is taken in a dose 125 mg/week. The general course dose makes from 3.75 to 5 g

In an acute hepatitis With — in the first 2 days of treatment — on 125 mg, after that — on 125 mg with an interval of 48 h. A course dose — 2.5 g

In chronic hepatitis C — in the first 2 days of treatment — on 250 mg, after that — on 125 mg with an interval of 48 h. A course dose in an initiation of treatment — 2.5 g. Further the medicament is taken in a dose 125 mg/week. The general course dose makes 5 g

At treatment of flu and other SARS — in the first 2 days of treatment on 125 mg, after that — on 125 mg with an interval of 48 h. The general course dose makes 750 mg.

For prevention of flu and other SARS is accepted on 125 mg for 6 weeks once a week.

For treatment of a herpes, Cytomegaloviral infection — in the first 2 days is accepted on 125 mg, after that — on 125 mg with an interval of 48 h. The general course dose makes 2.5 g

For decrease in degree of an immunosuppression as a part of complex therapy of the diseases which are followed by the secondary induced immunodeficience, and demanding immunocorrection — on 125–250 mg/week for 6 weeks. The maximum course dose makes 1.5 g. Depending on immunological indicators and a course of the disease the course of treatment can be repeated with an interval between courses of 4 weeks

In urogenital and respiratory clamidiosis accept 125 mg in the first 2 days, after that — on 125 mg with an interval of 48 h. A course dose — 1.25 g

as a part of complex therapy of neuroviral infections — infectious and allergic and viral encephalomyelitis (multiple sclerosis, a leukoencephalitis, uveoentsefalit also an encephalomeningitis) — in the first 2 days on 125 mg, after that — on 125 mg with an interval of 48 h. The course dose — from 1.5 to 1.75 g

Children is aged more senior than 7 years at uncomplicated forms of flu or other SARS the medicament is taken on 60 mg of 1 times a day in the 1, 2 and 4 day from an initiation of treatment. A course dose — 180 mg. At emergence of complications of flu or other SARS the medicament is taken on 60 mg/days in the 1, 2, 4 and 6 day from an initiation of treatment. A course dose — 240 mg.

Contraindication

Increased individual sensitivity to medicine components.

Side effects

from skin and hypodermic cellulose: allergic reactions, including itch, rash (in particular small tortoiseshell).

from a digestive tract: dispeptic phenomena (in particular nausea, heartburn).

Others: short-term fever.

Special instructions

Period of pregnancy and feeding by a breast. there is no experience of use of medicine during pregnancy and feeding by a breast therefore it is not necessary to appoint medicine during this period.

Children. Do not apply at children under 7 years.

Influence on ability to steer vehicles and to work with other mechanisms. Does not influence.

Interaction

It is compatible to antibiotics and means of traditional therapy of bacterial and viral diseases.

Overdose to

medicine overdose Cases amiksin ic are unknown to

.

Storage conditions

In original packing at a temperature not above 25 °C.

Specifications

Characteristics
Active ingredients Tiloron
Amount of active ingredient 125 mg
Applicant Interkhim
Code of automatic telephone exchange L03AX Other immunostimulators
Interaction with food Later
Light sensitivity Not sensitive
Market status The branded generic
Origin Chemical
Prescription status Without prescription
Primary packing blister
Producer INTERKHIM ODO
Quantity in packing 3 tablets
Release form tablets for internal use
Route of administration Oral
Sign Domestic
Storage temperature from 5 °C to 25 °C
Trade name Amiksin